GLPwatch
Papers (12034)
Page 172 of 201, ranked by citation count.
- Hormone copycats.
- Possible Attenuation of Early Weight Loss During Tirzepatide Therapy in a Patient Treated With Levosulpiride: A Case Report and Mechanistic Hypothesis.
- Antihyperglycemic medications for cardiovascular disease risk reduction.
- Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
- A Validated, Stability-Indicating HPLC Method for the Simultaneous Determination of Five Related Substances in Liraglutide Drug Substance.
- [Peptide hormone analogue-based pharmacotherapy for obesity is effective : What is the evidence on hard end points and the long-term course?]
- Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.
- Addressing the obesity challenge in plastic surgery - the role of liraglutide.
- Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.
- [Cardiac effects of glucagon-like peptide 1].
- Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy?
- Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study.
- Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance.
- Nmnat2 deficiency in the arcuate nucleus or paraventricular nucleus induces Sarm1-independent neuron loss and liraglutide-reversible obesity.
- From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems Model.
- Efimosfermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): Mechanism of Action, Clinical Development and Emerging Therapeutic Potential.
- Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice.
- Tirzepatide retention in iWAT with mesoporous polydopamine encapsulation enhances weight loss through leptin receptor signaling.
- Semaglutide in people with HIV-associated lipohypertrophy.
- Thermally Stressed Solid-State Stability of Semaglutide: Understanding the Influence of Temperature on Protein Content, Secondary Structure, Phase Transition, and Chemical Degradation.
- GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction.
- Association of inflammation with glycemic control, insulin sensitivity, and beta-cell function in diabetic cats.
- Comment on Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double‑Blind Single‑Centre Study.
- Patient Experiences With GLP-1 Receptor Agonists.
- Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.
- Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies.
- Semaglutide in Metabolic Medicine: <i>A Review on Clinical Applications and Emerging Therapeutics</i>.
- SemaGBA: A System Dynamics Model of the Semaglutide-Responsive Gut-Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight.
- Insights from changes in NDEV biomarkers of metabolism: Effects of PPARγ and GLP1 receptor agonists on brain metabolism.
- [Obesity and type 2 diabetes mellitus (Update 2026)].
- Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin.
- <sup>68</sup>Ga-labeled exendin-4 to image cardiac repair after myocardial infarction: From lizard venom to laboratory and beyond.
- Semaglutide attenuates neuroinflammation in male mice.
- [Effects of exendin-4 on extracellular matrix metabolism in human mesangial cells cultured in high glucose].
- Semaglutide in non-diabetic obese Chinese patients with acute coronary syndrome: a multicenter retrospective study.
- Exendin-4 enhances insulin-positive phenotype of human pluripotent stem cell-derived β cells during transplantation.
- Unimolecular GLP-1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta-Cell Survival and Glycaemic Regulation.
- Cost-Consequence Analysis of Semaglutide vs. Liraglutide for Managing Obese Prediabetic and Diabetic Patients in Saudi Arabia: A Single-Center Study.
- Glucagonlike peptide 1 analogs in diabetes care.
- Study on chitosan/carrageenan core-shell nanoparticles for oral co-administration of insulin/exenatide enhance insulin secretion in type 2 diabetes.
- In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER.
- [Liraglutide in polycystic ovary syndrome].
- A Short-Term Cost-Effectiveness Analysis of Tirzepatide Versus Semaglutide for the Treatment of Obesity in Greece.
- Semaglutide in Practice: Insights from a Retrospective Case Series at a Jharkhand Tertiary Care Hospital.
- Heart failure with preserved ejection fraction: updated diagnostic and therapeutic strategies. SEMI consensus document.
- Weight-Lowering Drugs and Natural Female Fertility-A Systematic Review and Meta-Analysis.
- Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.
- Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study.
- Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
- ATR-FTIR spectroscopy coupled with multivariate analysis for monitoring degradation and secondary structure transitions in therapeutic peptide formulations.
- Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets.
- Sensitive RP-LC Method Enabling PTM-Specific Quality Control and MS-Compatible Characterization of Fc-Containing GLP-1 Therapeutics.
- Impact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study.
- Effect of semaglutide on hidradenitis suppurativa disease control and quality of life: A case series.
- Pharmacological therapy in the obese patient: is it only a matter of fat loss?
- Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.
- Incident Diabetic Retinopathy after Adjunctive Tirzepatide Treatment for 1 Year in Adults with Type 1 Diabetes.
- Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes.
- Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report.
- Insulin degludec/liraglutide (Xultophy 100/3.6) for type 2 diabetes.